Available Brands
Did you find this information helpful?
Author Details
Written By
Sakshi Anil More
B. Pharm
Reviewed By
Dr. Tejashwin Adiga
MBBS
Last updated : 31 Mar 2026 | 09:31 AM (IST)
Want to know more?
Read Our Editorial Policy
Quick Summary
NILOTINIB
Last updated on 31 Mar 2026 | 09:31 AM (IST)
NILOTINIB
Background and Date of approval NILOTINIB
The U.S. FDA-approved Aprepitant for the treatment of chronic myeloid leukemia (CML) on October 29, 2007.
Uses of NILOTINIB
This medicine is used to treat a type of leukemia called Philadelphia chromosome-positive chronic myeloid leukemia (Ph-positive CML), a blood cancer with abnormal production of WBC. In adult and pediatric patients, it is used in a patient who is newly diagnosed with Chronic Myeloid Leukemia (CML) and those facing side effects from previous treatment. Additionally, it is also used in patients with no longer respond to the previous treatment including Imatinib.
How is NILOTINIB administered?
Take Nilotinib as advised by your physician. Swallow the medicine with a glass of water. Do not crush, chew, or open the medicine. Your doctor will decide the correct dose and duration for you based on your age, body weight, and disease condition. Do not stop taking Nilotinib unless your doctor advises you to stop.
Side Effects of NILOTINIB
The most common side effects of Aprepitant are nausea, vomiting, diarrhea, headache, muscle pain, stomach pain, hair loss, tiredness, constipation, slowing of growth in children, loss of appetite, sleeplessness, depression, anxiety, and musculoskeletal pain.
Serious side effects while taking Aprepitant are sudden weight gain, swelling in hands, feet, ankles, or face chest pain. blood pressure (high and low), discoloration of the tongue, lips, or skin (blue), abnormal heart (irregular heartbeat), hair loss, vision problems, stomach pain, vomiting of blood, and blood in stools. yellowing of the skin, eyes, and dark urine, high blood sugar levels, and sensitivity to light.
Warnings
Notify your doctor if you have or had a history of heart conditions (heart attack, abnormal electric signal), chest pain, brain stroke, or claudication ( condition of blood flow in the leg). Inform your doctor if you have liver or pancreas disorder, or suffering from a lack of potassium or magnesium. You need to tell your doctor about all the medications especially if you take medicine to lower your blood cholesterol. Tell your doctor about your underlying condition especially inform about if you have or ever had a hepatitis B infection; this medicine can activate HPV again which can be fatal in some cases.
Precautions
Do not take this medicine if you are allergic to Nilotinib or the other ingredients of this medicine. During the treatment, your doctor may conduct a regular blood test to monitor the liver and pancreas function, and the number of blood cells (WBC, RBC, platelets). Also to monitor the heart condition (prolongation of the QT interval), electrolytes in the body, and the level of sugar and fats. Before starting the treatment, inform your doctor if you are pregnant or think you may be pregnant or are planning to have a baby because your physician shall prescribe Aprepitant only if it is essential. Use effective contraception. Consult your doctor for more information.
Word of Advice
Store at room temperature below 30°C to 25°C. Keep out of sight and reach of children. Store in the original package in order to protect it from moisture. Contact your doctor for more concerns. Do not double the dose if missed the turn. Contact your doctor immediately if you double dose. Based on your condition your doctor may prescribe a lower dose. Nilotinib can be used by people aged 65 years and over with the same dose as other adults. Tell your doctor if you experience any irregular heartbeats or any signs of a heart condition because this can lead to serious complications like sudden death.
Frequently Asked Questions
Q1.
Can Nilotinib cause liver damage?
Nilotinib may cause liver function abnormalities, which may indicate liver damage. It is important to have regular blood tests to monitor your liver function while taking Nilotinib. If you experience symptoms of liver damage, such as jaundice or abdominal pain, you should contact your doctor immediately.
Q2.
How does Nilotinib differ from other medications used to treat chronic myeloid leukemia, such as Imatinib?
Imatinib, in its selectivity and potency. Nilotinib is more selective for the BCR-ABL protein that drives the growth of cancer cells, and it is more potent in inhibiting the activity of this protein. Nilotinib has also been shown to be effective in patients who have developed resistance to Imatinib.
Q3.
What are the potential long-term effects of Nilotinib on the body?
The potential long-term effects of Nilotinib on the body include cardiovascular events, such as hypertension, arrhythmias, and heart failure, as well as liver dysfunction, pancreatic enzyme elevation, and fluid retention. These side effects are generally rare, but they can occur in some patients.
Q4.
How to monitor the effects of Nilotinib over the course of treatment?
It is monitored through regular blood tests, electrocardiograms, and imaging studies. Blood tests can assess liver and kidney function, blood counts, and electrolyte levels. ECG can detect any changes in heart rhythm or function. Imaging studies, such as echocardiograms and chest X-rays, can evaluate the heart and lungs for any signs of damage or fluid accumulation.
Q5.
Who should not take Nilotinib?
Nilotinib should not be taken by pregnant or breastfeeding women, or by people with certain medical conditions such as severe liver or kidney disease, a history of pancreatitis, or a prolonged QT interval.
References
- Robert J. Thomson; Majid Moshirfar; Yasmyne Ronquillo; Tyrosine Kinase Inhibitors, [Revised on 21st Jan 2021]; [Accessed on 22st April 2023]; https://www.ncbi.nlm.nih.gov/books/NBK563322/
- Novartis Pharmaceuticals UK Ltd, Electronic Medicines Compendium (EMC), [Revised on May 2022], [Accessed on 21st April 2023], https://www.medicines.org.uk/emc/product/5852
- Novartis, US Food & Drug Administration, [Revised on Sep 2021], [Accessed on 21st April 2023], https://www.novartis.us/sites/www.novartis.us/files/tasigna.pdf?
Disclaimer
The drug information on this page is not a substitute for medical advice. It is meant for educational purposes only. For further details, consult your doctor about your medical condition to know if you are eligible to receive this treatment.
